Lexaria Bioscience Corp (LEXXW)

Etorro trading 970x250
Lexaria Bioscience Corp (LEXXW) Logo

About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Address: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7

Lexaria Bioscience Corp News and around…

Latest news about Lexaria Bioscience Corp (LEXXW) common stock and company :

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
13 Oct, 2021 FinancialContent
Lexaria's Technology Proven to Deliver Oral THC More Effectively
13 Oct, 2021 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
12 Oct, 2021 FinancialContent
IBN (InvestorBrandNetwork) Announces Latest Episode of Stock2Me Podcast Featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka
12 Oct, 2021 Yahoo! Finance

LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are act

DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete
05 Oct, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - October 5, 2021) - PCG Digital -- Lexaria Bioscience Corp (NASDAQ: LEXX) is making headlines again this week. In a study conducted by a leading independent testing facility, DehydraTECH™ 2.0 nicotine pouches easily outperformed generic nicotine benzoate pouches, hitting peak delivery rates within eight minutes, and then again at thirty minutes. The generic pouches hit peak at forty-five minutes.It's a significant disparity when comparing two similar products

Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
05 Oct, 2021 FinancialContent
BTV Highlights Promising Investment Opportunities
23 Sep, 2021 Yahoo! Finance

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - On Sat. Sept 25th at 5pm EST broadcast on FOX Business News - BTV-Business Television visits up-and-coming innovative investment opportunities.Discover Companies to Invest In - Watch their TV feature!Osisko Metals (TSXV: OM) (OTCQX: OMZNF) - As electric transportation rises in popularity, the zinc demand increases and Osisko is poised to take advantage with their advanced zinc projects.Fobi AI (TSXV: FOBI) (OTCQB: FOBIF) - BTV

Lexaria Takes Another Step Towards NDA Filing for DehydraTECH- CBD
14 Sep, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The most recent results from HYPER-H21-2, a human clinical study of the effects of Lexaria's DehydraTECHTM-processed CBD on blood pressure (BP) over a 24-hour ambulatory period, have moved the needle significantly in Lexaria's path towards an eventual New Drug Application (NDA). As a precursor to that, the company has begun an Investigational New Drug (IND) enabling program.Volunteers for HYPER-H21-2 who cope ...

Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 FinancialContent
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
08 Sep, 2021 FinancialContent
BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs
07 Sep, 2021 Yahoo! Finance

Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree.If you cannot view the video above, please visit: https://b-tv.com/investor-alert-lexaria-bioscience-the-modern-way-to-improve-oral-drugs/Lexaria Bioscience (NASDAQ: LEXX) Lexaria Bioscience is being featured on Bloomberg on Sept 6th to 10th, 2021,

Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
07 Sep, 2021 FinancialContent
Winning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology
17 Aug, 2021 Yahoo! Finance

Lexaria, delivering active ingredients to patients, could deliver for investors tooThe company that turns CBD into blood pressure control might be poised for a surgeTakeawaysOne critical component to over-the-counter drugs is how efficiently and how quickly (or not) they enter the bloodstream.Lexaria's DehydraTECHTM platform has proven to be an effective method to deliver active ingredients, with human tests demonstrating its ability with CBD as a hypertension treatment and animal tests demonstr

Lexaria's DehydraTECH-CBD Lowers Blood Pressure
29 Jul, 2021 FinancialContent
DehydraTECH(TM) - Enabled Consumer Products Now Available in Over 7,000 Stores
28 Jul, 2021 FinancialContent
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
28 Jul, 2021 FinancialContent
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
27 Jul, 2021 FinancialContent
Lexaria Receives US$3,817,643 From Warrant Exercises
26 Jul, 2021 FinancialContent
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
22 Jul, 2021 FinancialContent
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
21 Jul, 2021 FinancialContent
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council
15 Jul, 2021 FinancialContent
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan
13 Jul, 2021 FinancialContent
Lexaria Receives Patent Protection in Japan
13 Jul, 2021 FinancialContent
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
05 Jul, 2021 FinancialContent
Lexaria Announces 2021 Annual Meeting Results
29 Jun, 2021 FinancialContent
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
15 Jun, 2021 FinancialContent
Lexaria Provides Progress Report on Six R&D Programs
09 Jun, 2021 FinancialContent
Lexaria Announces Issuance of Options
08 Jun, 2021 FinancialContent
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
07 Jun, 2021 FinancialContent
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
03 Jun, 2021 FinancialContent

Lexaria Bioscience Corp (LEXXW) is a NASDAQ Common Stock listed in

970x250